SEHK:6990Biotechs
Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) Wins HER2 Approval, Is The Upside Already Priced In?
Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) just cleared an important hurdle. Positive phase III data for its HER2 antibody drug trastuzumab botidotin, together with Chinese regulatory approval, now anchors a key part of the investment story.
In the short term, the Sichuan Kelun-Biotech Biopharmaceutical share price has pulled back. The 1-day move is down 3.91% and the 30-day share price return is down 11.16%. However, the 90-day share price return is up 14.63% and the 3-year total...